Anna Sundlöv
11 – 20 of 35
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres
(
- Contribution to journal › Article
-
Mark
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
(
- Contribution to journal › Article
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
- 2021
-
Mark
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
(
- Contribution to journal › Article
-
Mark
Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
(
- Contribution to journal › Article
-
Mark
Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours
(
- Contribution to journal › Article
-
Mark
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms
(
- Contribution to journal › Article
- 2020
-
Mark
Characterisation of a hand-held CZT-based gamma camera for 177Lu imaging
(
- Contribution to journal › Article
-
Mark
Tailoring Radionuclide Therapy of Neuroendocrine Tumors - Bridging the Gaps
2020) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
- 2019
-
Mark
The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease
(
- Contribution to journal › Article